ʻO nā hoʻomaikaʻi nui o ka maʻi maʻi no ka Dermatitis Atopic

A HOLD Hoʻokuʻu ʻole 1 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

Ma nā wiki he 16, 70 pakeneka o nā maʻi me ka maʻi dermatitis atopic (AD) e loaʻa ana i ka lebrikizumab i hui pū ʻia me nā corticosteroids topical maʻamau (TCS) i loaʻa ma kahi o 75 pakeneka ka hoʻomaikaʻi ʻana i ka nui o ka maʻi maʻi (EASI-75*) i loko. ka hoʻokolokolo ADhere, ua hoʻolaha ʻo Eli Lilly a me Company (NYSE: LLY) i kēia lā ma ka 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Ua hōʻike pū ʻo Lebrikizumab, kahi mea hoʻopiʻi IL-13 hoʻokolokolo, i ka hoʻomaikaʻi ʻana i ka ʻili, ka hoʻopilikia ʻana i ka hiamoe, a me ka maikaʻi o ke ola ke hui pū ʻia me TCS, i hoʻohālikelike ʻia me kahi placebo a me TCS.

"ʻO ka ʻikepili ADhere o kēia lā, me nā hopena mai ka ADvocate monotherapy study, hōʻike i ka hiki no ka lebrikizumab e hōʻemi i ke kaumaha o ka maʻi a hāʻawi i ka hōʻoluʻolu no ka poʻe me ka dermatitis atopic i hoʻomalu ʻole ʻia ke hoʻohana wale ʻia a i hui pū ʻia me nā topical," wahi a Eric Simpson, MD, MCR, Polofesa o Dermatology a me ka Luna Hoʻokele o ka Clinical Research ma Oregon Health & Science University ma Portland, a me ka mea noiʻi nui o ADhere. "Ke kuhikuhi pono nei ʻo Lebrikizumab i ke ala IL-13, ka mea e hoʻokani nei i ke koʻikoʻi o kēia maʻi ʻehaʻeha. Hoʻoikaika kēia mau hopena i ko mākou ʻike no ka lebrikizumab i ka dermatitis atopic a kōkua i ka hoʻokumu ʻana i kahi koho lapaʻau hou.

ʻO Lebrikizumab kahi moʻolelo, monoclonal antibody (mAb) e hoʻopaʻa i ka interleukin 13 (IL-13) protein me ka pilina kiʻekiʻe e pale pono ai i ka hoʻokumu ʻana o IL-13Rα1/IL-4Rα (Type 2 receptor) e poloka ana i ka hōʻailona ma lalo o ka IL. -13 alahele.1-5 IL-13 ke koʻikoʻi o ke ʻano 2 ʻaʻa ma AD.6,7 I AD, IL-13 e hoʻopaʻa i nā hōʻailona a me nā hōʻailona e pili ana i ka pale ʻana o ka ʻili, ka ʻili, ka maʻi a me nā wahi paʻakikī o ka ʻili. .8

Ma waena o nā poʻe maʻi e lawe ana i ka lebrikizumab me ka TCS, 41 pakeneka i loaʻa i ka ʻili maʻemaʻe a kokoke paha (IGA) i nā pule he 16 i hoʻohālikelike ʻia me ka 22 pakeneka o nā maʻi e lawe ana i kahi placebo me TCS. Ma nā pule he 16, 70 pakeneka o nā maʻi e lawe ana i ka lebrikizumab me TCS i loaʻa i kahi pane EASI-75 i hoʻohālikelike ʻia me 42 pākēneka e lawe ana i kahi placebo me TCS. Ua ʻike ʻia nā ʻokoʻa ma waena o nā maʻi e loaʻa ana i ka lebrikizumab i hui pū me TCS a me kahi placebo me TCS ma mua o ʻehā pule no EASI-75.

ʻO nā maʻi i mālama ʻia me ka lebrikizumab a me TCS ua loaʻa pū kekahi i nā hoʻomaikaʻi koʻikoʻi i ka helu ma nā wahi hope lua koʻikoʻi e pili ana i ka hoʻomaʻemaʻe ʻana o ka ʻili a me ka ʻili ʻana, ka hoʻopili ʻana o ka ʻāʻī i ka hiamoe, a me nā ana o ke ola, ke hoʻohālikelike ʻia me kahi placebo me TCS. Ua ʻike ʻia nā ʻokoʻa koʻikoʻi o ka maʻi ma mua o ʻehā pule no ka maʻi ʻino, ke keʻakeʻa ʻana o ka ʻili i ka hiamoe, a me nā ana o ke ola.

Ua kūlike nā hopena palekana me nā haʻawina lebrikizumab mua ma AD. ʻO ka poʻe maʻi e lawe ana i ka lebrikizumab a me TCS, i hoʻohālikelike ʻia me kahi placebo a me TCS, ua hōʻike i kahi kiʻekiʻe o nā hanana ʻino (lebrikizumab me TCS: 43%, placebo me TCS: 35%). ʻO ka hapa nui o nā hanana ʻino he haʻahaʻa a haʻahaʻa paha i ka paʻakikī a ʻaʻole i alakaʻi i ka hoʻopau ʻana i ka mālama ʻana. ʻO ka maʻi maʻamau maʻamau no ka poʻe ma ka lebrikizumab he conjunctivitis (5%) a me ke poʻo ʻeha (5%).

"Ke hana nei ʻo Lilly e hoʻoikaika i ka poʻe me nā maʻi e pili ana i ka ʻili, e like me ka dermatitis atopic, e ola i ko lākou ola i ka mea hiki loa," wahi a Lotus Mallbris, MD, Ph.D., hope pelekikena o ka honua immunology development a me nā mea lapaʻau ma Lilly . "ʻIke mākou i ka pono koʻikoʻi no nā koho hou aʻe no ka poʻe i hiki ʻole ke mālama ʻia ka maʻi me nā topical. Manaʻo mākou e ʻike i nā hopena piha mai kā mākou papahana Phase 3 ākea a me ka holomua ʻana i ka lebrikizumab ma ka honua holoʻokoʻa.

Ua hoʻolaha aku nei ʻo Lilly i ka ʻikepili he 16 pule mai nā haʻawina ADvocate e hoʻomau nei, a ua hōʻike ʻia kahi hōʻike encore o nā hopena ma RAD 2022. Eia hou, e hōʻike ʻia nā ʻikepili lōʻihi mai nā haʻawina ADvocate i nā mahina e hiki mai ana.

"ʻO kēia mau hopena kahi hana hou aʻe i kā mākou kūpaʻa e hāʻawi i nā lāʻau lapaʻau hou e hana i kahi ʻokoʻa koʻikoʻi i nā maʻi. Manaʻo mākou i ka hoʻolaha ʻana i nā mea hou i nā mahina e hiki mai ana, "i ʻōlelo ai ʻo Karl Ziegelbauer, Ph.D., Almirall SA's Chief Scientific Officer.

Loaʻa iā Lilly nā kuleana kūʻokoʻa no ka hoʻomohala ʻana a me ka hoʻolaha ʻana o lebrikizumab ma United States a me ke koena o ka honua ma waho o ʻEulopa. Ua laikini ʻo Almirall i nā kuleana e hoʻomohala a kūʻai aku i ka lebrikizumab no ka mālama ʻana i nā hōʻailona dermatology, me AD, ma ʻEulopa.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...